The LINK® SP-CL® and LCU® Hip System PoroLink® (microporous) and HX® (CaP) coated is indicated for patients with mobility-limiting hip diseases, fractures or defects which cannot be treated by conservative or osteosynthetic procedures. The hip system is indicated for the following conditions: Primary and secondary coxarthrosis, Osteoarthritis, Necrosis of the femoral head, Femoral neck fractures. The stems are indicated for cementless use only.

Device Description

The LINK® SP-CL® and LCU® Systems include a straight stem (LCU® Hip Prosthesis) and an anatomically curved stem (SP-CL® Hip Prosthesis). Both stems are comprised of titanium alloy (Ti6A14V, ISO 5832-3, ASTM F136) available with corundum blasted PoroLink® (microporous) surface or HX® (calcium phosphate) (ASTM F1609) coated. The stems are available in a range of sizes, lengths, and offsets. The stems connect to femoral heads that are manufactured from Cobalt Chromium Molybdenum casting alloy (CoCrMo) or ceramic (BIOLOX® forte and BIOLOX® delta) via 12/14 Morse taper. In total joint use, the femoral head articulates against Signature Orthopedics' Origin crosslinked acetabular liners (#K121297) fixed in a cementless shell. Femoral heads part of this submission (BIOLOX® forte / delta head and LINK® Prosthesis Head B) are not intended for hemiarthroplasty use. Both the LCU® and SP-CL® stems are intended for cementless use to replace the hip joint.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and study information for the LINK® SP-CL® and LCU® Hip System:

Summary of Acceptance Criteria and Device Performance (as reported):

The document does not explicitly present a table of acceptance criteria with corresponding device performance metrics in the way one might see for digital health or AI-based devices with clear statistical thresholds (e.g., sensitivity, specificity). Instead, the acceptance criteria are implicit in the adherence to established international standards and the demonstration of substantial equivalence to predicate devices. The device performance is deemed acceptable if it meets the requirements of these standards.

Acceptance Criterion (Implicit)	Reported Device Performance (Implicitly Met)
Mechanical Performance (Fatigue Strength)	- Femoral stem fatigue tests per ISO 7206-4 and ISO 7206-8 were conducted. - Femoral neck segment fatigue tests per ISO 7206-6 were conducted.
Modular Connections (Fretting Corrosion)	- Modular Connections, Fretting Corrosion Testing per ASTM F1875-98 was conducted.
Range of Motion	- Range of Motion analysis of the LINK® SP-CL® and LCU® Hip Systems was conducted.
Component Testing (Ceramic Heads)	- Component Testing of ceramic heads was conducted.
Sterilization & Cleaning Effectiveness	- Procedures validated per AAMI ST 77:2006, AAMI ST79, ISO 17665-1, ISO 11138-3, AAMI TIR 12:2010, and AAMI TIR 30.
Endotoxin Levels	- Routine Endotoxin Testing performed according to AAMI ST 72.
Substantial Equivalence to Predicate Device (Overall Safety & Effectiveness)	- "The results of non-clinical performance testing demonstrate that the device is as safe, as effective, and substantially equivalent to the predicate device." - "The minor technological differences between the LINK® LCU® and SP-CL® Systems and its predicate device do not raise any new issues of safety or effectiveness." - Compared to DePuy Orthopaedics' Corail AMT Hip Prosthesis (#K123991, #K070554, #K042992) and LINK® Contour Ribbed Hip Prosthesis (#K854465). The subject device has "the same intended use and the same or similar indications, technological characteristics, and principles of operation as the predicate devices."

Study Information:

Sample size used for the test set and the data provenance:
- The document describes non-clinical performance testing which typically involves testing of physical samples (devices or components) rather than patient data. The specific number of devices tested for each non-clinical test (e.g., number of stems for fatigue testing) is not specified in this summary.
- Data Provenance: Not applicable in the context of clinical data. For non-clinical tests, the tests were conducted according to international standards (ISO, ASTM, AAMI). The location of the testing laboratories is not specified, but the manufacturing company is based in Norderstedt, Germany.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not applicable as this is a submission for a hip prosthesis based on non-clinical performance testing and substantial equivalence, not a study evaluating a diagnostic device that requires expert-established ground truth from clinical data.
Adjudication method (e.g. 2+1, 3+1, none) for the test set:
- Not applicable. There is no human adjudication of a test set in the context of the described non-clinical performance testing for a medical implant device.
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, an MRMC comparative effectiveness study was not done. This type of study is relevant for AI/radiology devices where human interpretation is involved. This submission is for a physical medical implant (hip prosthesis).
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Not applicable. This is not an algorithmic or AI-based device.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- For the non-clinical performance tests, the "ground truth" is established by the specifications and pass/fail criteria defined within the referenced international standards (e.g., ISO 7206, ASTM F1875, AAMI standards). The device's performance is compared against these predetermined engineering and material science specifications.
The sample size for the training set:
- Not applicable. This is not a machine learning or AI-based device that requires a training set.
How the ground truth for the training set was established:
- Not applicable. As there is no training set for an AI/ML algorithm.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three human profiles incorporated into its design. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 17, 2017

Waldemar Link GmbH & Co. KG Mr. André Von Malotki Regulatory Affairs Manager Oststraße 4-10 Norderstedt, Germany 22844

Re: K161840

Trade/Device Name: LINK® SP-CL® Hip System PoroLink® (microporous) and HX® (CaP) coated & LINK® LCU® Hip System PoroLink® (microporous) and HX® (CaP) coated Regulation Number: 21 CFR 888.3353 Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis Regulatory Class: Class II Product Code: LZO, MEH Dated: February 16, 2017 Received: February 16, 2017

Dear Mr. André Von Malotki:

This letter corrects our substantially equivalent letter of March 16, 2017.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply

{1}------------------------------------------------

with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Lori A. Wiggins -S

for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K161840

Device Name

LINK® SP-CL® Hip System PoroLink® (microporous) and HX® (CaP) coated & LINK® LCU® Hip System PoroLink® (microporous) and HX® (CaP) coated

Indications for Use (Describe)

The hip system is indicated for the following conditions:

Primary and secondary coxarthrosis
Osteoarthritis
Necrosis of the femoral head
Femoral neck fractures

The stems are indicated for cementless use only.

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

510(k) Submitter:	Waldemar Link GmbH & CO. KG
	Barkhausenweg 10
	22339 Hamburg, Germany
	Phone: +49-40-539950
	Facility Registration #:3004371426 (Oststraße 4-10)
Contact Person:	Waldemar Link GmbH & Co. KG
	André von Malotki (Regulatory Affairs)
	Oststraße 4-10
	Norderstedt, GERMANY 22844
	Phone: +49-40 53995-448
	Fax: +49-40 53995-174
	E-Mail: a.vonmalotki@linkhh.de
Date Prepared:	March 10th, 2017
Trade Name:	LINK® SP-CL® Hip System PoroLink® (microporous) andHX® (CaP) coated
	&
	LINK® LCU® Hip System PoroLink® (microporous) andHX® (CaP) coated
Common Name:	Hip Prosthesis
Classification Name:	Hip joint metal/ceramic/polymer semi-constrained cementedor nonporous uncemented prosthesis; 21 CFR §888.3353,product code LZO, MEH
Classification and Panel:	Class II, Orthopedic / 87
Predicate Devices:	Corail AMTTM Hip Prosthesis by DePuy Orthopaedics,#K123991 cleared September 16, 2013; #K070554 clearedSeptember 11, 2007; #K042992 cleared February 11, 2005
	LINK® Contour Ribbed Hip Prosthesis,#K854465 cleared February 2, 1986

{4}------------------------------------------------

Device Description:

Indications for Use:

-Primary and secondary coxarthrosis
-Osteoarthritis
Necrosis of the femoral head -
-Femoral neck fractures

The stems are indicated for cementless use only.

Comparison to Predicate Device:

Consistent with FDA's guidance document, "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]" (July 28, 2014) (510(k) Guidance Document), the LINK® SP-CL® and LCU® Hip Systems are substantially equivalent to DePuy Orthopaedics' Corail AMT Hip Prosthesis (#K123991, #K070554, #K042992) and the LINK® Contour Ribbed Hip Prosthesis (#K854465). The LINK® SP-CL® and LCU® Hip Systems have the same intended use and the same or similar indications, technological characteristics, and principles of operation as the predicate devices.

{5}------------------------------------------------

Performance Data:

Non-Clinical Performance and Conclusions:

Non-Clinical performance testing was conducted with consideration to "Guidance for Industry and FDA Staff, Non-Clinical Information for Femoral Stem Prosthesis, September 17, 2007".

Non-clinical performance testing included: femoral stem fatigue tests per ISO 7206-4 and ISO 7206-8; femoral neck segment fatigue tests per ISO 7206-6; ASTM F2068; Modular Connections, Fretting Corrosion Testing per ASTM F1875-98; Range of Motion analysis of the LINK® SP-CL® and LCU® Hip Systems and Component Testing of ceramic heads.

The results of non-clinical performance testing demonstrate that the device is as safe, as effective, and substantially equivalent to the predicate device.

Clinical Performance:

There was no clinical performance testing required for this device.

Cleaning, Sterilization and Routine Endotoxin Testing:

Sterilization and cleaning studies validate the procedures used, per the applicable standards of AAMI ST 77:2006, AAMI ST79, ISO 17665-1, ISO 11138-3, AAMI TIR 12:2010, and AAMI TIR 30.

Routine Endotoxin Testing is performed according to AAMI ST 72.

Conclusion:

The LINK® LCU® and SP-CL® Systems have the same intended use and the same or similar indications, technological characteristics, and principles of operation as its predicate device. The minor technological differences between the LINK® LCU® and SP-CL® Systems and its predicate device do not raise any new issues of safety or effectiveness.

The subject devices LINK® SP-CL® and LCU® Hip System PoroLink® (microporous) and HX® (CaP) coated are substantially equivalent to the predicate device identified in this premarket notification.

Regulation Number and Section

§ 888.3353 Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis.

(a)
Identification. A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.(b)
Classification. Class II.